GLP-1 cost savings strategies: How movement boosts ROI 

GLP-1 medications offer real potential for weight loss. But they also introduce significant financial risk for employers and health plans.

GLP-1 medications have reshaped obesity care. Their rapid rise has been fueled by strong clinical results, enthusiastic providers, and increasing demand from patients and executive sponsors. These medications often deliver meaningful short-term weight loss. But they can also carry a significant financial burden for employers and health plans.

GLP-1s can cost up to $10,000 per member annually¹. For self-insured employers and payers with large member populations, these costs scale quickly. Industry analysts now estimate that GLP-1 medications may account for up to 9% of total healthcare spending for some plans².

The return on investment, however, is not always clear. Many GLP-1 programs are not designed to deliver long-term value. Patients may lose weight, but often at the cost of lean muscle. Others discontinue treatment without establishing sustainable lifestyle habits. Weight regain is common³. Re-prescription is frequent⁴. And rising MSK costs often follow⁵.

The outcome is higher cost, lower value, and missed opportunity. But it doesn’t have to be that way.

Why GLP-1 programs lose ROI

GLP-1 medications are often deployed as standalone solutions. But long-term outcomes depend on the daily behaviors that sustain weight loss. The data reveals three major cost drivers:

• 70% of GLP-1 users discontinue within the first year³
• Up to two-thirds of lost weight is regained after stopping⁴
• Up to 39% of lean body mass is lost during treatment⁵

This lean mass loss affects more than the number on the scale. Muscle is essential for metabolism, movement, and injury prevention. As muscle is lost, metabolism slows. Members can become more prone to injury, fatigue, and chronic pain. That increases fall risk, reduces energy, and makes it harder to maintain weight loss without restarting medication.

The result is rising MSK claims, repeat prescribing, and higher absenteeism. These effects erode the very ROI that GLP-1 programs are meant to deliver.

Managing GLP-1 populations at scale

As GLP-1 medications become more widely adopted, employers and health plans are beginning to look beyond medication access alone. Rapid weight loss can introduce new health considerations, including muscle loss, declining physical function, and long-term weight maintenance challenges.

For organizations supporting large GLP-1 populations, the challenge is not only helping members lose weight, but ensuring those outcomes translate into sustainable improvements in cardiometabolic health.

Many healthcare leaders are exploring more comprehensive models that monitor emerging risks and support the daily behaviors that drive long-term health. This includes helping members stay active, maintain muscle mass, follow appropriate nutrition guidance, and remain engaged with their care between clinical visits.

Programs like Sword Pulse provide continuous lifestyle support that complements traditional care. Through always-on AI guidance, connected health data, and clinician oversight, Pulse helps members stay engaged with the habits that influence cardiometabolic outcomes.

For members using GLP-1 medications, this kind of continuous support can reinforce the behaviors that protect muscle mass, support metabolic health, and improve the likelihood that weight-loss results are sustained over time.

The role of behavior in GLP-1 outcomes

Long-term GLP-1 outcomes depend on the behaviors that support metabolic health between clinical visits. Physical activity plays an important role, helping preserve lean muscle and supporting sustainable weight loss.

Supporting physical activity can reduce GLP-1 cost risk by:

• Preserving lean muscle and supporting metabolism⁵
• Reducing re-prescriptions by building healthy routines
• Preparing members for success before starting treatment
• Lowering MSK risk and related claims from pain, falls, and injuries

This is a strategic lever that makes GLP-1 investment sustainable.

Four strategies to reduce GLP-1 program costs

Employers and health plans need structural solutions that support members before, during, and after GLP-1 treatment. These four interventions deliver the biggest financial and clinical impact:

1. Use pre-authorization to build healthy behaviors

Before approving GLP-1 medication, offer structured lifestyle support that helps members build habits needed for sustainable outcomes. This allows plans to:

• Identify members who may improve enough to postpone or avoid medication
• Build early lifestyle changes that drive better outcomes later
• Reduce unnecessary prescriptions and associated costs

This approach mirrors existing prehab models used before surgery. It sets a strong foundation and protects long-term results.

2. Support members during GLP-1 treatment

Supporting GLP-1 members with structured lifestyle support while they are actively taking medication:

• Preserves lean muscle⁵
• Improves energy and physical capacity
• Reinforces behavioral change for post-treatment success

Physical activity improves adherence and lowers the odds of rebound weight gain. It also boosts members’ confidence in managing their health beyond medication.

3. Post-treatment support

Once GLP-1 use ends, members become more vulnerable. Appetite returns, muscle has been lost, and motivation may fade. Without continued support, most members experience weight regain⁴ and escalating MSK risk⁵.

Continued movement helps members:

• Maintain their weight loss
• Rebuild strength
• Avoid relapse into high-cost care cycles

Structured physical activity provides a safety net at this critical turning point.

4. Choose outcomes-based partners

Maximize ROI by working with partners whose pricing is tied directly to member outcomes.

Outcomes-based vendors, like Sword, provide:

• Clear performance-linked pricing
• Member-level tracking and transparency
• Proven metrics across GLP-1-relevant populations

This approach reduces financial risk and aligns incentives around meaningful outcomes—not just access.

Real-world results from behavior change programs

Programs that support physical activity and behavior change can deliver measurable improvements in health engagement and functional outcomes. In populations relevant to GLP-1 treatment:

• 69% of “inactive” and “insufficiently active” members reach “active” or “healthy active” status within 10 weeks⁶
• Sedentary time reduced by 1 hour 22 minutes per day for previously “inactive” or “insufficiently active” members⁷
• Members completed 4.5 guided sessions per week⁸
• 91% of members reported feeling moderately or much better⁹

These results show measurable behavior change, which is exactly what GLP-1 programs often lack. Movement creates sustainable improvement in function, energy, and outcomes. When members move, they don’t just lose weight, they also gain strength, resilience, and better long-term health.

How to build a smarter GLP-1 cost strategy

If you want to reduce GLP-1 spend while improving health outcomes, start here:

Audit prescribing patterns

Look at duration, adherence, refill trends, and post-discontinuation MSK claims.

Layer structured movement into every phase

Offer movement-first care before, during, and after GLP-1 treatment.

Flag high-risk members early

Identify members who are inactive, have rising MSK costs, or lack adherence.

Choose outcomes-based partners

Work with vendors that only charge when members improve. Look for those who track and report on behavior change and MSK-related metrics.

Designing sustainable GLP-1 programs

GLP-1 medications offer meaningful weight loss potential. But long-term outcomes depend on the behaviors that sustain metabolic health. From muscle loss to weight regain to rising MSK claims, the downstream effects of inactive GLP-1 use are costly, invisible, and avoidable.

Instead, support GLP-1 prescriptions with movement as a clinical, financial, and behavioral tool to unlock lasting value from GLP-1 programs. Movement preserves lean mass, prevents MSK risk, reduces prescription churn, and builds the strength and stability needed to protect long-term outcomes. The smartest employers and health plans are already embedding structured movement into their benefit design. Not as an afterthought, but as a foundation.

Supporting sustainable GLP-1 outcomes

Employers and health plans are increasingly recognizing that successful GLP-1 programs require more than medication coverage. Supporting the behaviors that sustain weight loss helps protect both health outcomes and financial return.

Platforms like Sword Pulse help organizations deliver continuous lifestyle support across cardiometabolic populations, helping members stay engaged and maintain healthier outcomes over time.